Acute Porphyria Drug Database

Monograph

C09CA02 - Eprosartan
Not porphyrinogenic
NP

Rationale
Poorly absorbed, not metabolised.
Chemical description
Angiotensin II receptor antagonist. Weak inhibitor of CYP 2C9 in vitro. Biovailability only 13 % dependent on poor absorbtion. Excreted in unchanged form.
IPNet drug reports
Uneventful use reported in 1 patient with acute porphyria.

Similar drugs
Explore alternative drugs in similar therapeutic classes C09C / C09CA or go back.

Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia). Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway). What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors. We strive to improve it continuously.
Netherlands
Teveten · Teveten 400, filmomhulde tabletten 400 mg · Teveten 600, filmomhulde tabletten 600 mg
Belgium
Teveten · Teveten 600 mg compr. pellic.
United Kingdom
Eprosartan · Eprosartan 300mg tablets · Eprosartan 300mg/5ml oral solution · Eprosartan 300mg/5ml oral suspension · Eprosartan 400mg tablets · Eprosartan 600mg tablets · Teveten · Teveten 300mg tablets · Teveten 400mg tablets · Teveten 600mg tablets
Norway
Teveten
Poland
Teveten
Luxembourg
TEVETEN
Finland
Teveten
Latvia
Teveten
 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙